Natus Medical (NSDQ:BABY) said today it received an initial $20 million payment as part of a $120.7 million supply agreement between the Ministry of Health of Venezuela and its Buenos Aires, Argentina-based subsidiary Medix I.C.S.A. Through the deal, Natus Medical will provide medical equipment, supplies and services over 3 years, including certain 3rd party products. The Pleasanton, Calif.-based […]
Natus Medical (NSDQ:BABY) saw shares fall over 2% yesterday after releasing 2nd quarter earnings that missed the mark on earnings per share and revenue. The Pleasanton, Calif.-based company reported profits of $10.5 million, or 32¢ per share, on sales of $96 million for the 3 months ended June 30, 2016. Adjusted to exclude 1-time items, […]
Natus Medical (NSDQ:BABY) saw shares jump slightly after reporting Q4 and FY2015 earnings that beat the Street, with revenue numbers just squeaking under expectations. Pleasanton, Calif.-based Natus Medical Inc reported profits of $8.5 million, or 26¢ per share, on sales of $100 million for the 3 months ended December 31. That amounts to an 18.3% […]
The San Carlos, Calif.-based company said it expects to post sales of $81 million to $82 million for the 3 months ended June 30, down 5.8%-8.9% from its prior guidance of $86 million to $90 million.
Histogenics has a new face in the corner office with the appointment of Peter Greenleaf, an AstraZeneca veteran favored by the board for his experience moving products toward commercialization.
The company has its eyes on an end-stage pivotal trial for NeoCart, a device that uses patients’ own cells to regenerate knee cartilage.
The Indian government slashed reimbursement rates for drug-eluting stents by more than 61.5%, down to about $460 from roughly $1,200, aiming to give a boost to its domestic stents industry at the expense of the multinational players.
It’s the 2nd rate cut since October 2011, according to the Business Standard. India cut the rate of reimbursement for U.S.-made stents from 65,000 rupees (about $1,200) to 25,000 rupees (~$461), which is now the standard rate for stents regardless of origin, according to the newspaper.